Lyell Immunopharma Stock News

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies rai

Lyell Immunopharma Inc (LYEL) shares closed today 11.4% higher than it did at the end of yesterday. The stock is currently down 20.9% year-to-date, down 63.8% over the past 12 months, and down 63.8% over the past five years. Today, the Dow Jones Industrial Average rose 1.3%, and the S&P 500 rose 1.6%. Trading Activity Shares traded as high as $7.03 and as low as $5.50 this week.Shares closed 65.6% below its 52-week high and 38.9% above its 52-week low.Trading volume this week was 33.2% lower than the 10-day average and 11.6% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2194.9% The company's stock price performance over the past 12 months lags the peer average by 136.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL ), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK. LYL132 incorporates Epi-R, Lyell''s epigenetic reprogramming technology and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a GSK TCR therapy targeting NY-ESO-1 currently in pivotal clinical development. The cell surface antigen NY-ESO-1 is a clinically validated target present on many aggressive solid tumors. Lyell''s Epi-R technology is designed to address a major barrier to successful Adoptive Cell Therapy (ACT) by creating populations of T cells with properties of durable stemness.

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors. LYL132 is an investigational T-cell re

Lyell Immunopharma Inc (LYEL) shares closed today at 1.0% above its 52 week low of $6.06, giving the company a market cap of $1B. The stock is currently down 18.9% year-to-date, down 62.8% over the past 12 months, and down 62.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 56.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3387.6% The company's stock price performance over the past 12 months lags the peer average by 293.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw unusually-high trading volume on Wednesday . Approximately 32,971 shares changed hands during mid-day trading, a decline of 93% from the previous sessions volume of 459,476 shares.The stock last traded at $7.65 and had previously closed at $7.40. The business has a 50-day moving average of $11.16. Lyell Immunopharma []

Lyell Immunopharma Inc. (NASDAQ:LYEL) traded at $7.52 at close of the session on Monday, 12/20/21, made a downward move of -9.83% on its previous days price. Looking at the stock we see that its previous close was $8.34 with the days price range being $7.10 $8.385. In terms of its 52-week price range, LYEL Is Now An Ideal Time To Purchase Lyell Immunopharma Inc. (NASDAQ: LYEL) Stock? Read More »

Lyell Immunopharma, Inc. (NASDAQ:LYEL) reached a new 52-week low on Friday . The stock traded as low as $8.46 and last traded at $8.70, with a volume of 25477 shares changing hands. The stock had previously closed at $8.95. The firms 50-day moving average is $11.58. Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data []

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma , Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that its LyFE Manufacturing Center in Bothell, Washington has been commissioned and qualified in compliance with the U.S. Food and Drug Administrations (FDAs) Current Good Manufacturing Practices (cGMP).

Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares traded up 7.3% on Wednesday . The company traded as high as $9.89 and last traded at $9.85. 3,807 shares traded hands during trading, a decline of 99% from the average session volume of 421,339 shares. The stock had previously closed at $9.18. The companys fifty day simple moving average []

Lyell Immunopharmas (NASDAQ:LYEL) lock-up period will expire on Tuesday, December 14th. Lyell Immunopharma had issued 25,000,000 shares in its public offering on June 17th. The total size of the offering was $425,000,000 based on an initial share price of $17.00. After the expiration of Lyell Immunopharmas lock-up period, major shareholders and company insiders will be []

Baillie Gifford & Co. raised its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 65.2% during the third quarter, HoldingsChannel reports. The institutional investor owned 427,483 shares of the companys stock after purchasing an additional 168,660 shares during the quarter. Baillie Gifford & Co.s holdings in Lyell Immunopharma were worth $6,327,000 at the end of the []

Millennium Management LLC purchased a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 131,150 shares of the companys stock, valued at approximately $2,130,000. A number of other institutional investors have also recently added to or reduced their stakes in the stock. Cubist Systematic Strategies []

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as Chair of Lyells Board of Directors following the end of a temporary medical leave which was disclosed by the Company on September 30, 2021.